Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08MHM
|
|||
Former ID |
DND000007
|
|||
Drug Name |
PF-3758309
|
|||
Synonyms |
PF-309
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
Company |
Pfizer
|
|||
Structure |
Download2D MOL |
|||
Formula |
C25H30N8OS
|
|||
Canonical SMILES |
CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)NC(CN(C)C)C5=CC=CC=C5)SC=C2
|
|||
InChI |
1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1
|
|||
InChIKey |
AYCPARAPKDAOEN-LJQANCHMSA-N
|
|||
CAS Number |
CAS 898044-15-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:93751
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | PAK-4 protein kinase (PAK4) | Target Info | Inhibitor | [1] |
KEGG Pathway | ErbB signaling pathway | |||
Ras signaling pathway | ||||
Axon guidance | ||||
Focal adhesion | ||||
T cell receptor signaling pathway | ||||
Regulation of actin cytoskeleton | ||||
MicroRNAs in cancer | ||||
Renal cell carcinoma | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Inflammation mediated by chemokine and cytokine signaling pathway | ||||
Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
CDC42 signaling events | ||||
FGF signaling pathway | ||||
WikiPathways | ErbB Signaling Pathway | |||
Regulation of Actin Cytoskeleton | ||||
Focal Adhesion | ||||
Integrin-mediated Cell Adhesion |
References | Top | |||
---|---|---|---|---|
REF 1 | Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.